Webcast CME

How to Obtain AMA PRA Category 1 Credit

  1. Complete the Activity.
  2. Complete the CME posttest (each question must be answered correctly).
  3. Log into your myCME account.
  4. Complete the credit and evaluation form.
  5. Print your personalized CME certificate.
  6. Credit can only be claimed once for this activity.

Technical Requirements

2016 Pulmonary Hypertension Summit
Webcast Series

Evidence of Efficacy for Add-On
Therapy and Upfront Combination Therapy

Print this Content

Release Date: June 29, 2016
Expiration Date: June 29, 2018

Estimated Time of Completion: 45 minutes

Description

2016 Pulmonary Hypertension Summit Webcast Series reviews pulmonary hypertension diagnosis and treatment, including the most recent advances in the context of challenges faced by physicians and other health care providers caring for these patients.

This webcast reviews evidence of efficacy for add-on therapy and upfront combination therapy in the treatment of Pulmonary Arterial Hypertension (PAH).

Learning Objectives

  1. Explain why PAH patients treated with pulmonary vasodilators, right heart failure may progress despite an initial improvement in pulmonary vascular resistance.
  2. Describe how upfront combination therapy may be associated with less RV failure and better outcomes.
  3. The severity of PAH should be assessed by a panel of data derived from clinical assessment, exercise tests, biochemical markers, echocardiography and hemodynamic evaluation.
  4. Treatment strategy should be built upon the degree of PAH severity.
  5. Goal-oriented and outcome-oriented strategies are evidence based and should be considered as the standard of care in PAH management.

Target Audience

These activities are directed to physicians, physician assistants, and nurses with an interest in pulmonary hypertension.

Accreditation

The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of  0.75 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

Activity Directors and Faculty

Activity Directors

Raed A. Dweik, MD
Director, Pulmonary Vascular Program
Professor of Medicine
Department of Pulmonary and Critical Care Medicine
Respiratory Institute
Cleveland Clinic
Cleveland, OH

Samar Farha, MD
Pulmonary and Critical Care Medicine
Cleveland Clinic Abu Dhabi
Abu Dhabi, United Arab Emirates

Gustavo A. Heresi, MD
Medical Director, Pulmonary
Thromboendarterectomy Program
Department of Pulmonary and Critical Care Medicine
Respiratory Institute
Cleveland Clinic
Cleveland, OH

Franck Rahaghi, MD
Chairman, Department of Pulmonary Medicine
Director, Advanced Lung Disease Program
Respiratory Center Quality Officer
Director, Pulmonary Hypertension Clinic
Respiratory Center
Cleveland Clinic Florida
Weston, FL

Faculty

Harm Jan Bogaard, MD
VU University of Amsterdam
Amsterdam, Netherlands

Majdy Idrees, MD
President, Saudi Association for Pulmonary Hypertension
Co-chair, Eastern Mediterranean Pulmonary Hypertension Region, PVRI
Head, Pulmonary Vascular Unit
Department of Medicine
Prince Sultan Military Medical City
Riyadh, Saudi Arabia

CME Disclaimer

The information in this educational activity is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition. The viewpoints expressed in this CME activity are those of the authors/faculty. They do not represent an endorsement by The Cleveland Clinic Foundation. In no event will The Cleveland Clinic Foundation be liable for any decision made or action taken in reliance upon the information provided through this CME activity.

Disclosures

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty have indicated that they may have a relationship which, in the context of their contribution, could be perceived as a potential conflict of interest:

Raed A. Dweik, MD
  Bayer Healthcare Consulting, scientific advisory capacity
 
Gustavo A. Heresi, MD
  Bayer Healthcare Membership on advisory committee or review panels; Teaching and Speaking
  United Therapeutics Corporation Membership on advisory committee or review panels
 
Franck Rahaghi, MD
  Actelion; Bayer Healthcare; Gilead Sciences, Inc.; Lung Rx; United Therapeutics Corporation Consulting; Teaching and Speaking

The following faculty have indicated that they have no relationship which, in the context of their presentations, could be perceived as a potential conflict of interest:

Harm Jan Bogaard, MD
Samar Farha, MD
Majdy Idrees, MD

The Cleveland Clinic Foundation Center for Continuing Education acknowledges educational grants for partial support of this activity from:
Actelion Pharmaceuticals US, Inc.
Bayer HealthCare Pharmaceuticals
Gilead Sciences, Inc.
United Therapeutics Corporation and Lung Biotechnologies

This CME activity was produced by the Cleveland Clinic Foundation Center for Continuing Education and the Cleveland Clinic Respiratory Institute.